Society for Clinical Research Sites Welcomes Medidata as a Circle of Sustainability Sponsor
Ellicott City, Md., July 16, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced that Medidata Solutions, the leading global provider of cloud-based solutions for clinical research in life sciences, has joined SCRS’ Circle of Sustainability Sponsorship program. The program is designed to facilitate critical dialogue between industry stakeholders and clinical research sites, furthering SCRS’ mission of unifying the site community for greater sustainability.
“SCRS is proud to welcome Medidata as a Circle of Sustainability Sponsor,” said Christine Pierre, SCRS President. “The forward momentum of the clinical research industry is contingent upon improved relationships between sites, industry stakeholders, and solution-providers such as Medidata. This high-level partnership is symbolic of Medidata’s deep commitment to creating a more sustainable future for sites globally.”
As part of this program, Medidata’s president Glen de Vries will serve on the SCRS Global Impact Board, working with the organization’s leadership council to determine strategic initiatives for the society. Additionally, Medidata will sponsor and moderate the “Site Tank” session at the 2015 Global Site Solutions Summit in Amelia Island, Florida on October 8-11. During the session, which will take place on October 11 at 10:05 am, representatives from research sites will share innovative ideas on how technology can be used to enhance clinical trial operations.
“Our partnership with SCRS reflects Medidata’s dedication to ensuring research sites have the technology and resources they need to optimize productivity, gather high-quality data and create better patient experiences,” said de Vries. “We’re pleased to support SCRS and the important dialogue the society is facilitating to help the industry move clinical research forward.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
